SCHEDULE: Deep Track Capital Discloses 3.55% Stake in Apellis Pharma

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 4,532,374 shares, representing 3.55% of the outstanding common stock of Apellis Pharmaceuticals, Inc. as of March 31, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have collectively disclosed beneficial ownership of 4,532,374 shares of Apellis Pharmaceuticals, Inc. common stock.
• This holding represents 3.55% of the company's outstanding common stock.
• The filing is an amendment (Amendment No. 1) to a Schedule 13G, indicating a change in ownership or reporting status.
• The reporting date for this ownership is March 31, 2026.
• The total number of outstanding shares of common stock used for this calculation is 127,829,909, as per Apellis's 10-K filed on February 24, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance information about the company itself.

Positives

• Deep Track Capital has taken a significant stake, indicating confidence in Apellis Pharmaceuticals.
• The disclosure of a 3.55% stake suggests a substantial investment by a known investment firm.

Risks

• The filing does not explicitly mention any risks associated with this investment or the company itself.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Apellis Pharmaceuticals. The future outlook for Apellis would be derived from other company filings.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. Deep Track Capital's filing indicates a notable investment in the biotechnology sector, specifically within Apellis Pharmaceuticals.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in Apellis Pharmaceuticals, potentially influencing market perception and share price.
• Management: The company's management will be aware of the significant stake held by Deep Track Capital.

Next Steps

• Deep Track Capital will continue to monitor its investment in Apellis Pharmaceuticals.
• Further amendments to the Schedule 13G may be filed if ownership levels change significantly.

Key Dates

Keywords

Apellis Pharmaceuticals, Schedule 13G, Deep Track Capital, beneficial ownership, common stock, SEC filing, investment, biotechnology